دورية أكاديمية
Cost–Utility Analysis of Tenofovir Alafenamide and Entecavir in Chronic Hepatitis B Patients: A Markov Decision Model
| العنوان: | Cost–Utility Analysis of Tenofovir Alafenamide and Entecavir in Chronic Hepatitis B Patients: A Markov Decision Model |
|---|---|
| المؤلفون: | Chun-Huang Lai, Hon-Yi Shi, Cheng-En Tsai, Yuan-Chieh Yang, Si-Un Frank Chiu |
| المصدر: | Cancers, Vol 16, Iss 4, p 813 (2024) |
| بيانات النشر: | MDPI AG, 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | chronic hepatitis B, tenofovir alafenamide, entecavir, inverse probability of treatment weighting, cost–utility analysis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | From the perspective of health economics, the evaluation of drug-related cost effectiveness and clinical utility is crucial. We conducted a cost–utility analysis of two first-line drugs, tenofovir alafenamide (TAF) and entecavir (ETV), in the treatment of chronic hepatitis B (CHB) patients. We performed inverse probability of treatment weighting (IPTW) to match the independent variables between the two treatment groups. The incremental cost effectiveness ratio (ICER) of the two treatment groups was simulated using a decision tree with the Markov annual-cycle model. A total of 54 patients treated with TAF and 98 with ETV from January 2016 to December 2020 were enrolled. The total medical cost in the TAF group was NT$76,098 less than that in the ETV group, and TAF demonstrated more effectiveness than ETV by 3.19 quality-adjusted life years (QALYs). When the time horizon was set at 30 years, the ICER of the TAF group compared with the ETV group was −NT$23,878 per QALY, suggesting more cost savings for TAF. Additionally, with the application of TAF, over NT$366 million (approximately US$12 million) can be saved annually. TAF demonstrates cheaper medical costs and more favorable clinical QALYs than ETV. To balance health insurance benefits and cost effectiveness, TAF is the optimal treatment for CHB. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 16040813 2072-6694 |
| Relation: | https://www.mdpi.com/2072-6694/16/4/813; https://doaj.org/toc/2072-6694 |
| DOI: | 10.3390/cancers16040813 |
| URL الوصول: | https://doaj.org/article/d4683d4307704fa18ca2e8ef283ca815 |
| رقم الأكسشن: | edsdoj.4683d4307704fa18ca2e8ef283ca815 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 16040813 20726694 |
|---|---|
| DOI: | 10.3390/cancers16040813 |